| 4.4 -0.17 (-3.72%) | 03-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.33 |
1-year : | 5.76 |
| Resists | First : | 4.56 |
Second : | 4.94 |
| Pivot price | 4.5  |
|||
| Supports | First : | 3.96 |
Second : | 3.29 |
| MAs | MA(5) : | 4.54 |
MA(20) : | 4.46 |
| MA(100) : | 4.27 |
MA(250) : | 6.68 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 51.3 |
D(3) : | 55.9 |
| RSI | RSI(14): 49.3 |
|||
| 52-week | High : | 21.39 | Low : | 3.64 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NEUP ] has closed above bottom band by 33.9%. Bollinger Bands are 76.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 88 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.54 - 4.57 | 4.57 - 4.6 |
| Low: | 4.24 - 4.27 | 4.27 - 4.29 |
| Close: | 4.36 - 4.4 | 4.4 - 4.44 |
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Fri, 05 Dec 2025
HC Wainwright & Co. Maintains Neuphoria Therapeutics (NEUP) Buy Recommendation - Nasdaq
Wed, 05 Nov 2025
Does This Valuation Of Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Imply Investors Are Overpaying? - simplywall.st
Mon, 27 Oct 2025
Neuphoria Therapeutics (NASDAQ: NEUP) sets 15% trigger; rights plan expires 2026 - Stock Titan
Fri, 24 Oct 2025
Neuphoria Therapeutics Inc. (NEUP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Fri, 24 Oct 2025
Why Did NEUP Stock Surge 64% Today? - Stocktwits
Thu, 23 Oct 2025
Lynx1 Capital buys Neuphoria Therapeutics (NEUP) shares worth $3.28m - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 5 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 7.7 (%) |
| Held by Institutions | 50.3 (%) |
| Shares Short | 33 (K) |
| Shares Short P.Month | 41 (K) |
| EPS | -0.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.51 |
| Profit Margin | -37.8 % |
| Operating Margin | -12.5 % |
| Return on Assets (ttm) | -4.3 % |
| Return on Equity (ttm) | -26.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 2.78 |
| Sales Per Share | 2.78 |
| EBITDA (p.s.) | -0.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -6.38 |
| PEG Ratio | 0 |
| Price to Book value | 0.79 |
| Price to Sales | 1.58 |
| Price to Cash Flow | -10.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|